Anavex Life Sciences has released promising results from the latest phase of its ongoing study
into the efficacy of ANAVEX2-73 (blarcamesine) for treating Parkinson’s disease
dementia (PDD). The findings from the 48-week open-label extension phase
highlight significant improvements in clinical symptoms among participants,
suggesting a potential breakthrough in the management of this debilitating condition. 

The study, delayed by the COVID-19 pandemic, involved patients resuming treatment after an average
41-week pause. Despite this interruption, the results were compelling. Anavex
Life Sciences reported notable improvements in key metrics such as the Movement
Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II
and III, and the Clinical Global Impression-Improvement (CGI-I). This suggests
that blarcamesine could play a crucial role in slowing, or even reversing,
Parkinson’s disease symptoms. 

Dr. Christopher U. Missling, CEO of Anavex, was optimistic about the findings. “The data suggests
ANAVEX2-73’s potential capability to address the urgent, unmet needs of
Parkinson’s disease patients,” he stated. These results align with earlier
data, which showed a relative improvement of 18.9% over 14 weeks in MDS-UPDRS
total scores for high-dose blarcamesine users compared to a placebo group. 

The study’s participants, who were also on stable anti-PD medication regimens, reported
improvements in cognitive assessments and sleep behavior.  

Such results underscore the broader therapeutic benefits of Anavex’s
investigational drug beyond motor symptom management. 

However, caution is warranted. Due to the small sample sizes and the study’s design, these results
should be interpreted carefully. Despite this, many participants have opted to
continue treatment under compassionate use programs, indicating a robust demand
for ongoing access to blarcamesine. 

As Anavex Life Sciences prepares for its forthcoming 6-month Parkinson’s study, the medical
community remains hopeful that ANAVEX2-73 will confirm its efficacy and safety,
potentially offering a new beacon of hope for those battling Parkinson’s
disease dementia. Read this article for additional information. 

More about Anavex on https://www.cnn.com/markets/stocks/AVXL